Nanoscope Therapeutics to Present at the BIO CEO and Investor Conference
DALLAS, Feb. 6, 2025 -- Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel g ...
Nanoscope Therapeutics Announces Presentations at Upcoming Medical Meetings
DALLAS, Feb. 4, 2025 -- Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therap ...
Nanoscope Therapeutics to Present at the 21st Annual Advanced Therapies Week Conference
DALLAS, Jan. 20, 2025 -- Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therap ...
Nanoscope Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
DALLAS, Jan. 9, 2025 -- Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therap ...
Industry Veteran and Gene Therapy Manufacturing Expert, Ray Kaczmarek, Joins Nanoscope as Chief Technical and Manufacturing Officer
DALLAS, Dec. 5, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and geographic atrophy (GA), today announced t ...
Nanoscope’s Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress
DALLAS, Dec. 2, 2024 — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases (IRDs) and geographic atrophy (GA) secondary to mac ...
Nanoscope Announces Presentations at the Advanced Therapies USA Congress in Philadelphia
DALLAS, Nov. 11, 2024 -- Nanoscope Therapeutics, Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degeneration (AMD), ...
Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors
DALLAS Nov. 7, 2024 Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today ...
Nanoscope Presented Positive 2-Year Randomized, Controlled Trial Results of MCO-010 for Retinitis Pigmentosa
DALLAS-Oct. 31, 2024 -- Nanoscope Therapeutics, Inc., a BLA filing-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that positive 2-year results ...
Nanoscope Publishes Breakthrough Showing MCO-010 Treatment Arrests Neurodegeneration
DALLAS, Oct. 21, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases today announced a breakthrough discovery ...
Nanoscope Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2024
DALLAS, Oct. 15, 2024 -- Nanoscope Therapeutics, Inc., a BLA filing-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Nanoscope will present ...
Nanoscope Announces Plans to Submit BLA for MCO-010 to Treat Retinitis Pigmentosa
Productive FDA meeting paves the way for BLA submission for MCO-010 in Q1 2025 DALLAS, TX -- Oct. 10, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company develo ...
Nanoscope Therapeutics Licenses Optogenetic CatCh Technology
Innovative technology incorporated in Nanoscope's gene therapy offers hope for restoring vision in genetically caused visual impairments DALLAS, Sept. 30, 2024 -- Nanoscope Therapeutics Inc., a clinic ...
Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona
Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona DALLAS, Sept. 19, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company ...
Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona
DALLAS, Sept. 19, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases (IRDs) and geographic atrophy second ...
Nanoscope Therapeutics Announces Presentations at Euretina Innovation Spotlight and Ophthalmology Futures Forum in Barcelona
DALLAS Sept. 16, 2024 -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, and geographic atrophy today announced presentat ...
Nanoscope Therapeutics Announces End-of-Phase 2 Meeting with U.S. FDA and Plan to Initiate a Phase 3 Clinical Trial of MCO-010 to Treat Stargardt Macular Degeneration
Phase 3 Registrational Trial Expected to Commence in Near-termDALLAS, Sept. 12, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal ...
Nanoscope Therapeutics Announces Presentations at the Retina Society and Advanced Therapies Europe Annual Meetings in Lisbon
DALLAS, Sept. 9, 2024 -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced presentations at the Retina Soci ...
Nanoscope Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
DALLAS, TX -- Aug. 8, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations ( ...
Nanoscope Therapeutics to Present at the 2024 American Society of Retina Specialists (ASRS) Annual Scientific Meeting
DALLAS, July 10, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), ...